Chinese biopharmaceutical company Dizal (SSE:688192) announced on Saturday the presentation of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

One study evaluated DZD6008, an investigational fourth-generation EGFR TKI, in pre-treated NSCLC patients with EGFR C797X mutations following progression on third-generation EGFR TKI treatment. The other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.

Findings showed that DZD6008 demonstrated strong and durable anti-tumour activity in patients relapsed from third-generation EGFR TKI with a favourable safety profile. The majority of patients (82.1%) had tumour shrinkage following DZD6008 treatment, and a higher response rate is expected with longer treatment. Tumour response was found to be durable, with 6 months progression free survival (PFS) rates at 70.6% and 61.8%, respectively for 40 mg and 60 mg cohorts. The median duration of response (DoR) was not reached.

Among 47 enrolled treatment-naive patients with advanced NSCLC, golidocitinib plus sintilimab following chemo-immunotherapy demonstrated encouraging and durable anti-tumour efficacy, particularly in those with high PD-L1 expression. Profound improvement of irAE was noticed, Dizal said.